Kuvatris Therapeutics, Inc.
PXMDDelisted Aug 8, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811623
Kuvatris Therapeutics, Inc. was delisted on Aug 8, 2025; its insiders filed their last Form 4 on Mar 14, 2024; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:24 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 |
|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K |
| Reported | – | Mar 30, 2023 |
| Revenue | $0 | $0 |
| Operating expenses | $16.1M | $10.6M |
| Research and development | $3.91M | $1.79M |
| Selling, general and administrative | $12.2M | $8.82M |
| Operating income | -$16.1M | -$10.6M |
| Interest expense | $9.16K | $5.24K |
| Income tax | $0 | – |
| Net income | -$18.3M | -$14.8M |
| EPS, basic | $-11.00 | $-1.69 |
| EPS, diluted | $-11.00 | $-1.69 |
| Weighted shares, basic | 1.66M | 8.74M |
| Weighted shares, diluted | 1.66M | 8.74M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 |
|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K |
| Reported | – | Mar 30, 2023 |
| Cash and equivalents | $4.71M | $1.90M |
| Short-term investments | $0 | $0 |
| Total current assets | $5.68M | $2.20M |
| Total assets | $5.68M | $2.20M |
| Accounts payable | – | $722.0K |
| Total current liabilities | $1.80M | $2.10M |
| Total liabilities | $2.30M | $2.10M |
| Shareholders' equity | $3.39M | $108.8K |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 |
|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K |
| Reported | – | Mar 30, 2023 |
| Operating cash flow | -$10.8M | -$6.07M |
| Stock-based compensation | $5.20M | $4.42M |
| Financing cash flow | $13.6M | $7.53M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jan 13, 2026 | 126.3M | – | SEC |
| Sep 20, 2024 | 10.9M | −33.8% | SEC |
| May 13, 2024 | 7.78M | −46.8% | SEC |
| Mar 11, 2024 | 7.41M | −45.3% | SEC |
| Nov 15, 2023 | 2.29M | −80.5% | SEC |
| Aug 9, 2023 | 16.4M | +39.5% | SEC |
| May 15, 2023 | 14.6M | – | SEC |
| Mar 29, 2023 | 13.6M | – | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.